Bristol-Myers Squibb BMY
SEC filings (XBRL) · quarterly · fiscal year ends December 31
Data change on Oct 12, 2026: 1 shares outstanding value for Q1 2021 removed, no figure in the filings (BMY shares_outstanding Q1 2021 blanked: two independent pulls disagree; left blank until reviewed).
Data change on Oct 12, 2026: 1 shares outstanding value for Q3 2020 removed, no figure in the filings (BMY shares_outstanding Q3 2020 blanked: two independent pulls disagree; left blank until reviewed).
Data change on Oct 12, 2026: 1 shares outstanding value for Q4 2020 removed, no figure in the filings (BMY shares_outstanding Q4 2020 blanked: two independent pulls disagree; left blank until reviewed).
Pick a second metric to compare.
Source: SEC EDGAR 10-Q/10-K XBRL, CIK 14272; every value is traced to its filing on EDGAR. Retrieved Oct 11, 2026. Quarters labelled by fiscal quarter with the calendar period end. Q4 = annual minus Q1–Q3; cash-flow quarters derived from year-to-date figures.
Last 84 quarters
| Q3 2024Sep 30, 2024 | Q4 2024Dec 31, 2024 | Q1 2025Mar 31, 2025 | Q2 2025Jun 30, 2025 | Q3 2025Sep 30, 2025 | Q4 2025Dec 31, 2025 | Q1 2026Mar 31, 2026 | Q2 2026Jun 30, 2026 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $11.9B | $12.3B | $11.2B | $12.3B | $12.2B | $12.5B | $11.5B | $13.0B |
| Operating income | — No figure for Q3 2024: no candidate tag (OperatingIncomeLoss) on the income statement of 0000014272-24-000147 (R2.htm); the statement presents no such line | — No figure for Q4 2024: no candidate tag (OperatingIncomeLoss) on the income statement of 0000014272-25-000039 (R3.htm); the statement presents no such line | — No figure for Q1 2025: no candidate tag (OperatingIncomeLoss) on the income statement of 0000014272-25-000091 (R2.htm); the statement presents no such line | — No figure for Q2 2025: no candidate tag (OperatingIncomeLoss) on the income statement of 0000014272-25-000131 (R2.htm); the statement presents no such line | — No figure for Q3 2025: no candidate tag (OperatingIncomeLoss) on the income statement of 0000014272-25-000149 (R2.htm); the statement presents no such line | — No figure for Q4 2025: no candidate tag (OperatingIncomeLoss) on the income statement of 0000014272-26-000004 (R3.htm); the statement presents no such line | — No figure for Q1 2026: no candidate tag (OperatingIncomeLoss) on the income statement of 0000014272-26-000010 (R2.htm); the statement presents no such line | — No figure for Q2 2026: no candidate tag (OperatingIncomeLoss) on the income statement of 0000014272-26-000020 (R2.htm); the statement presents no such line |
| Net income | $1.2B | $0.1B | $2.5B | $1.3B | $2.2B | $1.1B | $2.7B | $3.3B |
| Capital spending | $0.3B | $0.4B | $0.3B | $0.4B | $0.3B | $0.4B | $0.3B | $0.3B |
| Operating cash flow | $5.6B | $4.4B | $2.0B | $3.9B | $6.3B | $2.0B | $1.1B | $3.4B |
| Free cash flow | $5.3B | $4.1B | $1.7B | $3.6B | $6.0B | $1.6B | $0.8B | $3.1B |
| Capex / operating cash flow | 5.8% | 8.5% | 13.3% | 9.2% | 5.1% | 18.7% | 31.4% | 9.0% |
| Shares outstanding | 2.028B | 2.029B | 2.035B | 2.035B | 2.036B | 2.036B | 2.042B | 2.043B |
| Share count change, y/y | −0.3% | +0.4% | +0.4% | +0.4% | +0.4% | +0.4% | +0.3% | +0.4% |
| Diluted shares (weighted avg.) | 2.031B | — No figure for Q4 2024: fiscal Q4: the 10-K presents no 3-month weighted average; never derived | 2.040B | 2.038B | 2.039B | — No figure for Q4 2025: fiscal Q4: the 10-K presents no 3-month weighted average; never derived | 2.047B | 2.048B |
Operating income: Not presented by the company: no candidate tag (OperatingIncomeLoss) on the income statement of 0000014272-17-000132 (R2.htm); the statement presents no such line.
— Diluted shares (weighted avg.): No figure for Q4 2024: fiscal Q4: the 10-K presents no 3-month weighted average; never derived
— Diluted shares (weighted avg.): No figure for Q4 2025: fiscal Q4: the 10-K presents no 3-month weighted average; never derived
Diluted shares (weighted avg.): fiscal Q4 is blank because the 10-K gives 12-month figures only.
XBRL tags used
| Revenue | Revenues | Mar 2017 to Jun 2026 |
|---|---|---|
| Operating income | Not presented by the company: no candidate tag (OperatingIncomeLoss) on the income statement of 0000014272-17-000132 (R2.htm); the statement presents no such line | |
| Net income | NetIncomeLoss | Mar 2017 to Jun 2026 |
| Capital spending | PaymentsToAcquirePropertyPlantAndEquipment | Mar 2017 to Jun 2026 |
| Operating cash flow | NetCashProvidedByUsedInOperatingActivities | Mar 2017 to Jun 2026 |
| Free cash flow | ocf - capex: NetCashProvidedByUsedInOperatingActivities, PaymentsToAcquirePropertyPlantAndEquipment | Mar 2017 to Jun 2026 |
| Capex / operating cash flow | capex / ocf * 100: PaymentsToAcquirePropertyPlantAndEquipment, NetCashProvidedByUsedInOperatingActivities | Mar 2017 to Jun 2026 |
| Shares outstanding | dei:EntityCommonStockSharesOutstanding | Mar 2017 to Jun 2026 |
| Diluted shares (weighted avg.) | WeightedAverageNumberOfDilutedSharesOutstanding | Mar 2017 to Jun 2026 |
Where a company changed tags, each quarter uses the tag it was reported under; the newest tag is primary.